ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2021-4-2-92-100ojrdrt-178Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCLINICAL CASESКомбинированное хирургическое и интервенционно-радиологическое циторедукционное лечение больной с диссеминированной высокодиференцированной нейроэндокринной опухолью подвздошной кишкиCombined Surgical/Interventional-Radiological Cytoreduction in a Patient with Disseminated Highly Differentiated Neuroendocrine Ileal Tumorhttps://orcid.org/0000-0002-6965-8236ПерегудовН. А.PeregudovN. A.

Перегудов Николай Александрович — врач-ординатор НИИ клинической и экспериментальной радиологии 

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow, Russia 115478

peregudov.nikolaj95@mail.ruhttps://orcid.org/0000-0003-2315-6457ФалалееваЛ. А.FalaleevaL. A.

Фалалеева Лидия Александровна — врач-ординатор НИИ Клинической онкологии 

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow, Russia 115478

https://orcid.org/0000-0002-0927-6885СергееваО. Н.SergeevaO. N.

Сергеева Ольга Николаевна — старший научный сотрудник, кандидат медицинских наук

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow, Russia 115478

https://orcid.org/0000-0002-5548-1724МарковичА. А.MarkovichA. A.

Маркович Алла Анатольевна — старший научный сотрудник, кандидат медицинских наук

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow, Russia 115478

https://orcid.org/0000-0001-7185-7165ДолгушинБ. И.DolgushinB. I.

Долгушин Борис Иванович — заместитель директора по научной и лечебной работе — директор НИИ клинической и экспериментальной радиологии, академик РАН, доктор медицинских наук, профессор

SPIN-код: 2623-8259

115478, Москва, Каширское шоссе, 24

24 Kashirskoye Highway, Moscow, Russia 115478

Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation2021220620214292100Copyright © Перегудов Н.А., Фалалеева Л.А., Сергеева О.Н., Маркович А.А., Долгушин Б.И., 20212021Перегудов Н.А., Фалалеева Л.А., Сергеева О.Н., Маркович А.А., Долгушин Б.И.Peregudov N.A., Falaleeva L.A., Sergeeva O.N., Markovich A.A., Dolgushin B.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/178

Продемонстрирован комбинированный подход к циторедукции у больной нейроэндокринной опухолью G1 подвздошной кишки с множественными билобарными метастазами G2 в печени, исходно рассматриваемой в качестве кандидата только для лекарственной терапии. Первым этапом была проведена лапароскопическая резекция илеоцекального сегмента кишки, за которой последовало интервенционно-радиологическое вмешательство — двухэтапная селективная трансартериальная масляная химиоэмболизация печени с блеомицином. В результате была достигнута циторедукция 90 %, купирование клинических проявлений, нормализация хромогранина А и серотонина. Пациентка продолжает наблюдаться без признаков прогрессирования более 4 лет с момента установления диагноза. Показано, что мультимодальное лечение пациента со своевременным включением в него интервенционно-радиологических вмешательств позволяет добиться длительных благоприятных результатов у пациентов с распространенной стадией заболевания.

A combined approach to cytoreduction in a patient with a neuroendocrine tumor G1 the ileum with multiple bilobar metastases G2 in the liver, originally considered as a candidate only for drug therapy, has been demonstrated. The first stage was laparoscopic resection of the ileocecal segment of the intestine, followed by interventional radiological intervention — a two-stage selective transarterial oil chemoembolization of the liver with bleomycin. As a result, 90 % cytoreduction, suppression of clinical manifestations, normalization of chromogranin A and serotonin were achieved. The patient continues to be observed without signs of progression for more than 4 years from the moment of diagnosis. It is shown that multidisciplinary treatment of patient with timely inclusion of interventional-radiological interventions allows achieving long-term favorable results in patients with advanced stage of disease.

нейроэндокринная опухольподвздошная кишкаметастазы в печенитрансартериальная химиоэмболизацияэффективностьциторедукцияинтервенционная радиологияileum neuroendocrine tumorliver metastasestransarterial chemoembolizationeffeсtcytoreductioninterventional radiologyReferencesHallet J, Law CHL, Cukier M. Exploring the rising incidence of neuroendocrine tumors: A populationbased analysis of epidemiology, metastatic presentation, and outcomes. First published: 13 October 2014. DOI: 10.1002/cncr.29099.Hallet J, Law CHL, Cukier M. Exploring the rising incidence of neuroendocrine tumors: A populationbased analysis of epidemiology, metastatic presentation, and outcomes. First published: 13 October 2014. DOI: 10.1002/cncr.29099.Sacksteina PE, O’Neilbc S, Neugut I, et al. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years Author links open overlay panel. July 2008. DOI: 10.1053/j.seminoncol.2018.07.001.Sacksteina PE, O’Neilbc S, Neugut I, et al. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years Author links open overlay panel. July 2008. DOI: 10.1053/j.seminoncol.2018.07.001.Riihimaki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases inneuroendocrine tumors. Int J Cancer. 2016;139:2679-86. DOI: 10.1002/ijc.30400.Riihimaki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases inneuroendocrine tumors. Int J Cancer. 2016;139:2679-86. DOI: 10.1002/ijc.30400.Godwin J. Carcinoid tumors. An analysis of 2,837 cases. Cancer. 1975;36:560-9. DOI: 10.1002/1097-0142(197508)36:2%3C560::AIDCNCR2820360235%3E3.0.CO;2-4.Godwin J. Carcinoid tumors. An analysis of 2,837 cases. Cancer. 1975;36:560-9. DOI: 10.1002/1097-0142(197508)36:2%3C560::AIDCNCR2820360235%3E3.0.CO;2-4.McDermott E, Guduric B, Brennan M. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg. 1994;81:1007-9. DOI: 10.1002/bjs.1800810725.McDermott E, Guduric B, Brennan M. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg. 1994;81:1007-9. DOI: 10.1002/bjs.1800810725.Zappa M, Abdel-Rehim M. Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. DOI: 10.1007/s11523012-0219-8.Zappa M, Abdel-Rehim M. Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. DOI: 10.1007/s11523012-0219-8.Xiang J, Zhang X, Beal E, et al. Hepatic Resection for Nonfunctional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter? Ann Surg Oncol. 2018. DOI: 10.21037/hbsn.2020.04.02.Xiang J, Zhang X, Beal E, et al. Hepatic Resection for Nonfunctional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter? Ann Surg Oncol. 2018. DOI: 10.21037/hbsn.2020.04.02.Chamberlain R, Canes D, Brown K, et al. Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg. 2000;190:432-45. DOI: 10.1016/s1072-7515(00)00222-2.Chamberlain R, Canes D, Brown K, et al. Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg. 2000;190:432-45. DOI: 10.1016/s1072-7515(00)00222-2.Cloyd J, Ejaz A, Konda B, et al. Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surgery and Nutrition. 2020;9(4):440=51. DOI: 10.21037/hbsn.2020.04.02.Cloyd J, Ejaz A, Konda B, et al. Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surgery and Nutrition. 2020;9(4):440=51. DOI: 10.21037/hbsn.2020.04.02.Gurusamy K, Ramamoorthy R, Sharma D, et al. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev 2009;(2):CD007060. DOI: 10.1002/14651858. CD007060.pub2.Gurusamy K, Ramamoorthy R, Sharma D, et al. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev 2009;(2):CD007060. DOI: 10.1002/14651858. CD007060.pub2.Pavel M, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157-76. DOI: 10.1159/000335597.Pavel M, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157-76. DOI: 10.1159/000335597.Maxwell J, Sherman S, O’Dorisio T, et al. Liverdirected surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016;159(1):320-35. DOI: 10.1016/j.surg.2015.05.040.Maxwell J, Sherman S, O’Dorisio T, et al. Liverdirected surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016;159(1):320-35. DOI: 10.1016/j.surg.2015.05.040.Morgan R, Pommier S, Pommier R. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163(1):218-25. DOI: 10.1016/j.surg.2017.05.030.Morgan R, Pommier S, Pommier R. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163(1):218-25. DOI: 10.1016/j.surg.2017.05.030.Gupta S, Yao J, Ahrar K. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the m.d. anderson experience. Cancer J. 2003;9(4):261-7. DOI: 10.1097/00130404-200307000-00008.Gupta S, Yao J, Ahrar K. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the m.d. anderson experience. Cancer J. 2003;9(4):261-7. DOI: 10.1097/00130404-200307000-00008.Mendoza-Elias N, Morrison J, Valeshabad A, et al. Decision Making for Selection of Transarterial Locoregional Therapy of Metastatic Neuroendocrine Tumors. Sem Intervent Radiol. 2017;34(02):101-8. DOI: 10.1055/s-0037-1602590.Mendoza-Elias N, Morrison J, Valeshabad A, et al. Decision Making for Selection of Transarterial Locoregional Therapy of Metastatic Neuroendocrine Tumors. Sem Intervent Radiol. 2017;34(02):101-8. DOI: 10.1055/s-0037-1602590.Mayo SC, Pawlik TM. Surgical management of neuroendocrine tumors: treatment of localized and metastatic disease. Oncology (Williston Park) 2011;25:806, 808, 810.Mayo SC, Pawlik TM. Surgical management of neuroendocrine tumors: treatment of localized and metastatic disease. Oncology (Williston Park) 2011;25:806, 808, 810.Mayo S, de Jong M, Bloomston M, et al. Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis. Ann Surg Oncol. 2011;18(13):3657-65. DOI: 10.1245/s10434-011-1832-y.Mayo S, de Jong M, Bloomston M, et al. Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis. Ann Surg Oncol. 2011;18(13):3657-65. DOI: 10.1245/s10434-011-1832-y.Osborne D, Zervos E, Strosberg J, et al. Improved Outcome With Cytoreduction Versus Embolization for Symptomatic Hepatic Metastases of Carcinoid and Neuroendocrine Tumors. Ann Surg Oncol. 2006;13(4):572-81. DOI: 10.1245/aso.2006.03.071.Osborne D, Zervos E, Strosberg J, et al. Improved Outcome With Cytoreduction Versus Embolization for Symptomatic Hepatic Metastases of Carcinoid and Neuroendocrine Tumors. Ann Surg Oncol. 2006;13(4):572-81. DOI: 10.1245/aso.2006.03.071.Eriksson B, Larsson E, Skogseid B, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998 Dec 1;83(11):2293-301. PMID: 9840528.Eriksson B, Larsson E, Skogseid B, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998 Dec 1;83(11):2293-301. PMID: 9840528.

The authors declare that there are no conflicts of interest present.